Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Wave Life Sciences Ltd. - Ordinary Shares (NQ:WVE)

6.350 +0.020 (+0.32%)
Streaming Delayed Price Updated: 3:07 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Wave Life Sciences Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
Earnings Scheduled For March 4, 2025
Via Benzinga
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
What's Next: WAVE Life Sciences's Earnings Preview
Via Benzinga
Deep Dive Into WAVE Life Sciences Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
What Analysts Are Saying About WAVE Life Sciences Stock
Via Benzinga
Earnings Scheduled For May 8, 2025
Via Benzinga
WAVE Life Sciences Earnings Preview
Via Benzinga
The Analyst Verdict: WAVE Life Sciences In The Eyes Of 4 Experts
Via Benzinga
Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year
Wave Life plans a 2026 NDA filing for WVE-N531 after positive Phase 2 data in Duchenne muscular dystrophy, showing functional gains and biomarker improvements. 
Via Benzinga
Exposures Product Safety
1 Brand-New Big Reason to Buy This Biotech Stock Right Now
This stock currently has a good balance of risk and potential rewards. 
Via The Motley Fool
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.
Korro Bio is lagging Wave Life Sciences. But an analyst says it could ultimately be the leader. 
Via Investor's Business Daily
WAVE Life Sciences Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
Oklo, CleanSpark And Wolfspeed Are Among Top 7 Mid Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio?
These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio? 
Via Benzinga
This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans
Wave Life Sciences' WVE-006 demonstrates first-ever RNA editing in humans for alpha-1 antitrypsin deficiency, showing favorable safety and efficacy in early trial results. GSK holds global license... 
Via Benzinga
Wave Life Sciences Just Edited RNA — And Shares Hit The Stratosphere
The company is testing its new technology in patients with a genetic disease that impacts the lungs. 
Via Investor's Business Daily
United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics
These two could become direct competitors relatively soon. 
Via The Motley Fool
General Motors To $42? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Stitch Fix Reports Weak Earnings, Joins KB Home And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Crude Oil Gains Over 1%; BioVie Shares Plunge
Via Benzinga
Exposures Fossil Fuels
Nasdaq Surges 100 Points; Thor Industries Earnings Top Views
Via Benzinga
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug
Wave Life Sciences reveals positive interim data from its Phase 2 FORWARD-53 study on WVE-N531 for Duchenne muscular dystrophy patients. Results show improved muscle health, dystrophin production, and... 
Via Benzinga
Wave Life Sciences, Nio, Li Auto, Tesla And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating
William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1... 
Via Benzinga
WVE Stock Earnings: WAVE Life Sciences Misses EPS, Misses Revenue for Q2 2024
WVE stock results show that WAVE Life Sciences missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
What's Going On With Wave Life Sciences Stock On Tuesday?
Wave Life Sciences reports Phase 1b/2a SELECT-HD trial results for WVE-003 in Huntington's disease, demonstrates promise as a disease-modifying therapy. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.